Overview

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Status:
Active, not recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma

Phase:

Phase 1

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Rituximab
Spebrutinib